Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Dapas

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|April 26, 2016
Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of NutraceuticalsAlessandra Bosutti, Fabrizio Zanconati, Gabriele Grassi, et al.
European Journal of Biochemistry|July 19, 2003
Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomersBarbara Dapas, Gianluca Tell, Andrea Scaloni, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 27, 2019
A rapid and specific method to simultaneously quantify eukaryotic elongation factor 1A1 and A2 protein levels in cancer cellsAlessandra Bosutti, Odeta Kalaja, Fabrizio Zanconati, et al.
International Journal of Molecular Sciences|November 27, 2024
Non-Coding RNAs as Potential Diagnostic/Prognostic Markers for Hepatocellular CarcinomaFederica Tonon, Chiara Grassi, Domenico Tierno, et al.
Pharmaceutics|April 23, 2022
An Overview of siRNA Delivery Strategies for Urological CancersNadia Halib, Nicola Pavan, Carlo Trombetta, et al.
World Journal of Gastroenterology|February 28, 2014
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentialsBruna Scaggiante, Maryam Kazemi, Gabriele Pozzato, et al.
Molecular Pharmaceutics|August 5, 2010
Simultaneous release and ADME processes of poorly water-soluble drugs: mathematical modelingGabriele Grassi, Dritan Hasa, Dario Voinovich, et al.
International Journal of Pharmaceutics|April 21, 2016
Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effectsBruna Scaggiante, Rosella Farra, Barbara Dapas, et al.
Current Drug Metabolism|January 13, 2011
Improving siRNA bio-distribution and minimizing side effectsBruna Scaggiante, Barbara Dapas, Rossella Farra, et al.
Biochimie|February 11, 2010
Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6Rossella Farra, Barbara Dapas, Gabriele Pozzato, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Anti-Cancer Agents in Medicinal Chemistry|April 26, 2016
Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of NutraceuticalsAlessandra Bosutti, Fabrizio Zanconati, Gabriele Grassi, et al.
European Journal of Biochemistry|July 19, 2003
Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomersBarbara Dapas, Gianluca Tell, Andrea Scaloni, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 27, 2019
A rapid and specific method to simultaneously quantify eukaryotic elongation factor 1A1 and A2 protein levels in cancer cellsAlessandra Bosutti, Odeta Kalaja, Fabrizio Zanconati, et al.
International Journal of Molecular Sciences|November 27, 2024
Non-Coding RNAs as Potential Diagnostic/Prognostic Markers for Hepatocellular CarcinomaFederica Tonon, Chiara Grassi, Domenico Tierno, et al.
Pharmaceutics|April 23, 2022
An Overview of siRNA Delivery Strategies for Urological CancersNadia Halib, Nicola Pavan, Carlo Trombetta, et al.
World Journal of Gastroenterology|February 28, 2014
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentialsBruna Scaggiante, Maryam Kazemi, Gabriele Pozzato, et al.
Molecular Pharmaceutics|August 5, 2010
Simultaneous release and ADME processes of poorly water-soluble drugs: mathematical modelingGabriele Grassi, Dritan Hasa, Dario Voinovich, et al.
International Journal of Pharmaceutics|April 21, 2016
Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effectsBruna Scaggiante, Rosella Farra, Barbara Dapas, et al.
Current Drug Metabolism|January 13, 2011
Improving siRNA bio-distribution and minimizing side effectsBruna Scaggiante, Barbara Dapas, Rossella Farra, et al.
Biochimie|February 11, 2010
Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6Rossella Farra, Barbara Dapas, Gabriele Pozzato, et al.
Pageof 6